{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:11:38Z","timestamp":1790817098304,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010772","name":"Percy Falks Foundation for Research into Prostate Cancer and Breast Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018650","name":"Percy Falk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006285","name":"Magnus Bergvalls Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012538","name":"Swedish Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012538","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejca.2026.116261","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:50:33Z","timestamp":1769705433000},"page":"116261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Vaginal tamoxifen \u2013 A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen"],"prefix":"10.1016","volume":"236","author":[{"given":"Sara","family":"Nyback","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger Sundstr\u00f6m","family":"Poromaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Lindman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica Lind\u00e9n","family":"Hirschberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Kopp","family":"Kallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wikman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora Kunovac","family":"Kallak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2026.116261_bib1","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/13697137.2025.2514029","article-title":"Enhancing quality of life: addressing vulvovaginal atrophy and urinary tract symptoms","volume":"28","author":"Hirschberg","year":"2025","journal-title":"Climacteric"},{"issue":"9","key":"10.1016\/j.ejca.2026.116261_bib2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/GME.0000000000001609","article-title":"The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society","volume":"27","year":"2020","journal-title":"Menopause"},{"issue":"6","key":"10.1016\/j.ejca.2026.116261_bib3","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1634\/theoncologist.2015-0007","article-title":"Symptoms and symptom attribution among women on endocrine therapy for breast cancer","volume":"20","author":"Rosenberg","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2026.116261_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.maturitas.2021.04.005","article-title":"Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: an EMAS clinical guide","volume":"148","author":"Hirschberg","year":"2021","journal-title":"Maturitas"},{"issue":"1","key":"10.1016\/j.ejca.2026.116261_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2010.08.035","article-title":"Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer","volume":"204","author":"Baumgart","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116261_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/GME.0b013e31826560da","article-title":"Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer","volume":"20","author":"Baumgart","year":"2013","journal-title":"Menopause"},{"issue":"5","key":"10.1016\/j.ejca.2026.116261_bib7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/13697137.2011.642427","article-title":"Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients","volume":"15","author":"Kunovac Kallak","year":"2012","journal-title":"Climacteric"},{"issue":"4","key":"10.1016\/j.ejca.2026.116261_bib8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/annonc\/mdj127","article-title":"Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors","volume":"17","author":"Kendall","year":"2006","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116261_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/GME.0b013e31829e41df","article-title":"Aromatase inhibitors affect vaginal proliferation and steroid hormone receptors","volume":"21","author":"Kallak","year":"2014","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.ejca.2026.116261_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1006263818115","article-title":"Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B","volume":"55","author":"Fallowfield","year":"1999","journal-title":"Breast Cancer Res Treat"},{"issue":"22","key":"10.1016\/j.ejca.2026.116261_bib11","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","article-title":"Tamoxifen in the treatment of breast cancer","volume":"339","author":"Osborne","year":"1998","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2026.116261_bib12","first-page":"285","article-title":"Weekly vaginal administration of tamoxifen for three months in postmenopausal women with vulvar and vaginal atrophy: a possible new treatment approach?","volume":"46","author":"Chollet","year":"2019","journal-title":"CEOG"},{"issue":"3","key":"10.1016\/j.ejca.2026.116261_bib13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0014-2999(84)90493-X","article-title":"An evaluation of tamoxifen as a partial agonist by classical receptor theory \u2014 an explanation of the dual action of tamoxifen","volume":"103","author":"Macnab","year":"1984","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116261_bib14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-006-9260-6","article-title":"ATAC Trialistsa9 Group. Quality of Life of Postmenopausal Women in the ATAC (\u201cArimidex\u201d, Tamoxifen, Alone or in Combination) Trial after Completion of 5 Years\u2019 Adjuvant Treatment for Early Breast Cancer","volume":"100","author":"Cella","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.ejca.2026.116261_bib15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/13697137.2023.2211763","article-title":"Pharmacokinetics, safety and preliminary pharmacodynamic evaluation of DARE-VVA1: a soft gelatin capsule containing tamoxifen for the treatment of vulvovaginal atrophy","volume":"26","author":"Thurman","year":"2023","journal-title":"Climacteric"},{"issue":"11","key":"10.1016\/j.ejca.2026.116261_bib16","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1080\/14656566.2024.2391009","article-title":"Ospemifene and vulvovaginal atrophy: an update of the clinical profile for post-menopausal women","volume":"25","author":"Di Carlo","year":"2024","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10.1016\/j.ejca.2026.116261_bib17","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1097\/00006250-200606000-00057","article-title":"American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion. No. 336: Tamoxifen and Uterine Cancer","volume":"107","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.ejca.2026.116261_bib18","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/humrep\/16.12.2496","article-title":"Model of counter-current transfer from vagina to urethra in postmenopausal women","volume":"16","author":"Cicinelli","year":"2001","journal-title":"Hum Reprod"},{"issue":"5","key":"10.1016\/j.ejca.2026.116261_bib19","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/GME.0000000000001497","volume":"27","author":"Hirschberg","year":"2020","journal-title":"Menopause"},{"issue":"12","key":"10.1016\/j.ejca.2026.116261_bib20","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2020-0417","volume":"25","author":"S\u00e1nchez-Rovira","year":"2020","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ejca.2026.116261_bib21","first-page":"695","article-title":"Short-term effects of tamoxifen, medroxyprogesterone acetate, and their combination on receptor kinetics and 17 beta-hydroxysteroid dehydrogenase in human endometrium","volume":"66","author":"Neumannov\u00e1","year":"1985","journal-title":"Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.ejca.2026.116261_bib22","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1200\/JCO.1991.9.7.1283","article-title":"Tamoxifen in premenopausal patients with metastatic breast cancer: a review","volume":"9","author":"Sunderland","year":"1991","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116261_bib23","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/IGC.0b013e3181a47cbe","article-title":"Effect of tamoxifen on the endometrium and the menstrual cycle of premenopausal breast cancer patients","volume":"19","author":"Buijs","year":"2009","journal-title":"Int J Gynecol Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2026.116261_bib24","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1200\/JCO.2015.64.8675","article-title":"Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial","volume":"34","author":"Ribi","year":"2016","journal-title":"JCO"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926000419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926000419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:17:41Z","timestamp":1779380261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926000419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":24,"alternative-id":["S0959804926000419"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116261","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaginal tamoxifen \u2013 A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116261","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116261"}}